Menu

Sweet and Low

Glucose activates sleep-promoting neurons in the mouse hypothalamus.

Oct 1, 2015
Ashley P. Taylor

EDITOR'S CHOICE IN NEUROSCIENCE

SUGAR COMA MODEL: An injection of glucose into the ventrolateral preoptic nucleus (VLPO) of the anterior hypothalamus fuels ATP production in sleep-promoting neurons located in the VLPO. This boost in cellular ATP closes potassium channels (KATP), leading to neuronal excitation and the onset of sleep. When the VLPO sleep-promoting neurons fire, they inhibit arousal-promoting areas of the brain (inset, orange; sleep-promoting areas in blue). Glucose can also reduce arousal by directly inhibiting orexin-releasing neurons.
See full infographic: WEB | PDF
© KIMBERLY BATTISTA. INSET REDRAWN WITH PERMISSION FROM THIERRY GALLOPIN

The paper
C. Varin et al., “Glucose induces slow-wave sleep by exciting the sleep-promoting neurons in the ventrolateral preoptic nucleus: A new link between sleep and metabolism,” J Neurosci, 35:9900-11, 2015.

That drowsy feeling after a big meal—the so-called food coma—may actually be the result of increased neuronal activity. New research in mice suggests that sugar excites neurons in a brain region, called the ventrolateral preoptic nucleus (VLPO) of the hypothalamus, that induces sleep.

“What [the researchers] show is that these ventrolateral preoptic neurons are glucose responsive, and they show that in times of high glucose, they fire more,” says Harvard University neuroscientist Clifford Saper, who was not involved with the study. “If you’ve ever had a big meal, and you get sleepy afterward...this may be part of the reason why.”

About 20 years ago, Saper discovered that sleep-promoting neurons within the VLPO usher the brain into the first stage of the sleep cycle, slow-wave sleep, by inhibiting the organ’s arousal systems. When awake, these arousal systems inhibit VLPO sleep neurons. This two-way inhibition, says Saper, ensures that we are either awake or asleep, depending on which set of neurons has the upper hand, but that we spend little time—often just seconds—in between.

One such arousal system is a group of hypothalamic neurons that release neuropeptides called orexins (also known as hypocretins); loss of orexin neurons in humans leads to narcolepsy. Researchers have shown that glucose inhibits orexin neurons in vitro, inspiring Thierry Gallopin at ESPCI ParisTech in France to investigate how glucose affects the sleep-promoting neurons of the VLPO. “If glucose is able to inhibit this arousal system, my hypothesis is that glucose could, in turn, excite sleep-promoting neurons,” says Gallopin.

So Gallopin and his colleagues injected glucose—in concentrations at or beyond physiological limits—into the VLPOs of mice and monitored their sleep for two hours. The mice fell asleep faster and slept longer after an injection with glucose than they did after being given a glucose-free solution.

Brain-slice experiments revealed that VLPO sleep neurons fire more in the presence of glucose. More specifically, it’s the energy molecule ATP, a product of glucose metabolism, that is responsible. These cells contain potassium channels that close in response to ATP, thereby making the neurons fire more readily. This leads to the inhibition of orexin neurons and other arousal regions of the brain.

With its arousal centers quieted, the brain goes to sleep. “The slow waves seem to be the natural state of the brain if it is not being stimulated,” explains Saper in an email. Previous studies have shown that a slab of cortex disconnected from the rest of the brain will enter a slow-wave state spontaneously. This scenario isn’t quite the same as sleep, Saper adds, given that the brain sample cannot wake up. “A slow-wave state that cannot be interrupted would more accurately be called a coma.”

Thankfully, a “food coma” is less a catatonic state and more the result of a brain sent off to sleep by a molecular lullaby.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.